WHO ICTRP trial
A phase Ia, dose-finding study to assess the safety and immunogenicity of an Orf…
CTIS2024-511266-36-00 · EU Clinical Trials Information System · Not Recruiting
Key facts
| Trial ID | CTIS2024-511266-36-00 |
|---|---|
| Public title | A phase Ia, dose-finding study to assess the safety and immunogenicity of an Orf virus-based COVID-19 vaccine booster (Prime-2-CoV_Beta) in healthy adults |
| Scientific title | - PRiME2_21_1 |
| Primary sponsor | Universitaetsklinikum Tuebingen AöR |
| Registry | EU Clinical Trials Information System |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): Yes Therapeutic exploratory (Phase II): No Therapeutic confirmatory - (Phase III): No Therapeutic use - (Phase IV): No |
| Countries | Germany |
| Conditions | The clinical trial itself does not investigate a medical condition or disease. Rather, the safety and immunogenicity of a vaccine against SARS-CoV-2 infection is being investigated. MedDRA version: 24.0Level: LLTClassification code… |
| Registration date | Nov 3, 2024 |
| Target size | 72 |
| Secondary IDs | NCT05389319;U1111-1303-8564;2021-001191-42 |
| Registry page | euclinicaltrials.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: